Rocket Lab Shares Climb 2.8% to $78.14, But Neutron Delays Add $15M Costs
Rocket Lab shares closed at $78.14, up 2.83% in the most recent trading session. The company also logged a 174% rise in 2025 after a 30% December spike fueled by SpaceX IPO rumors, yet its Neutron rocket debut slipped to mid-2026, adding $15M in quarterly delay costs.
1. Strong Launch Performance and Revenue Growth
Rocket Lab completed a record 21 Electron missions in 2025, up from 17 missions the prior year, driving annual launch revenue to approximately $180 million. The company’s total backlog now exceeds $2.0 billion, bolstered by an $816 million contract for a constellation deployment. Analysts project that annual sales could more than double to $1.2 billion by 2027, reflecting growing demand for both small-satellite rideshares and dedicated launches.
2. Neutron Rocket Development and Timeline Delays
The reusable Neutron medium-lift vehicle, designed to carry up to 13,000 kilograms to low-Earth orbit, has seen its maiden flight slip from a late-2025 target to mid-2026 or later. Each quarter of delay is estimated to add roughly $15 million in development costs, contributing to a cumulative investment of nearly $360 million by the end of 2025. The first launch is now expected no earlier than the second quarter of 2026, with further setbacks possible if engine integration or regulatory approvals extend beyond current projections.
3. Competitive Landscape and Pricing Pressures
Neutron contracts are priced between $50 million and $55 million per launch, compared with roughly $8.4 million per Electron mission. Yet SpaceX’s Falcon 9, carrying up to 17,500 kilograms, offers per-flight pricing in the $67 million to $70 million range for dedicated launches and can leverage internal costs near $15 million to undercut market rates. Emerging entrants like Firefly Aerospace also plan medium-lift offerings by late 2026, intensifying competition for constellation operators and government payloads.
4. Financial Outlook and Valuation Risks
Despite record revenue growth and a strong backlog, Rocket Lab remains cash-flow negative on Neutron development and ongoing R&D, with operating cash outflows persisting into 2026. High capital expenditures and potential supply-chain or site-approval delays at Wallops Island could necessitate additional equity raises, risking dilution at current valuations. Trading at approximately 48 times forward revenue estimates, the stock’s valuation presumes sustained 30% annual growth—a challenging benchmark given execution risks and competitive headwinds.